Tech Company Financing Transactions
TransCode Therapeutics Funding Round
TransCode Therapeutics secured a $10 million financing round on 3/25/2025. Backers included private investors.
Transaction Overview
Company Name
Announced On
3/25/2025
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The Company intends to use the proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, including related IND-enabling studies, and for working capital and other general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
73b Chapel Street
Newton, MA 02458
USA
Newton, MA 02458
USA
Phone
Undisclosed
Email Address
Overview
TransCode Therapeutics is a Boston-based biotechnology company focused on oncology. TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tom Fitzgerald
Browse more venture capital transactions:
Prev: 3/25/2025: Protecht Group venture capital transaction
Next: 3/25/2025: Sunday venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs